COR · News · 20260805N

Revenue Performance and Mix

Cencora, Inc. · 2026-08-05 · Importance 36 · Surprise 14 · No source text

Cencora’s fiscal third-quarter revenue increased 5.1% year over year to $84.8 billion for the quarter ended June 30, 2026. Growth was driven by higher volume in both the U.S. Healthcare Solutions and International Healthcare Solutions segments, particularly specialty pharmaceuticals and GLP-1 diabetes and weight-loss products. The company’s pharmaceutical-centric strategy and specialty demand supported the quarterly performance despite manufacturer list-price reductions and pricing pressure.

Key facts

• In the fiscal third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. source
• One report stated revenue at $84.75 billion for Q3 2026 and reported net income of $763.52 million and diluted EPS of $3.94. source
• On a GAAP basis, diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter. source
• Cencora reported adjusted diluted EPS of $4.48 for Q3 2026, beating consensus estimates (Zacks cited $4.37 and other outlets cited $4.35). source
• Multiple reports credit 'specialty strength' and 'specialty-business momentum' (including US and International Healthcare Solutions segments) with driving the quarter's performance. source

Impact estimates